Research programme: infectious disease therapeutics - Sanofi Genzyme Corporation/Oswaldo Cruz Foundation

Drug Profile

Research programme: infectious disease therapeutics - Sanofi Genzyme Corporation/Oswaldo Cruz Foundation

Alternative Names: Anti-TGFβ monoclonal antibodies - Sanofi Genzyme/Oswaldo Cruz Foundation; Anti-transforming growth factor beta monoclonal antibodies - Sanofi Genzyme/Oswaldo Cruz Foundation; Chagas disease therapeutics - Sanofi Genzyme/Oswaldo Cruz Foundation

Latest Information Update: 16 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genzyme Corporation; Oswaldo Cruz Foundation
  • Developer Oswaldo Cruz Foundation; Sanofi Genzyme
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Trypanosomiasis

Most Recent Events

  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
  • 21 Sep 2010 This programme is still active
  • 23 Jul 2007 Early research in Trypanosomiasis in Latin America (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top